NCT05725434View on ClinicalTrials.gov

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis

PHASE3UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

April 1, 2023

Study Completion Date

July 31, 2023

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CT-P47 AI (tocilizumab)

CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2

BIOLOGICAL

CT-P47 PFS (tocilizumab)

CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY